As the final quarter of 2020 approaches, so does the 2020/2021 flu season. As a result, the demand for COVID-19 testing is only expected to intensify, with those providing solutions set to be rewarded handsomely, according to Wall Street pros.Biocept (BIOC) is among those fighting the good fight against the deadly virus, offering polymerase chain reaction (PCR) tests. These tests are used to directly detect the presence of an antigen, rather than the presence of the body’s immune response, or antibodies.On September 16, BIOC announced that it has received more than 35,000 COVID-19 specimens to-date, reflecting a roughly 14,000 increase …read more
Source:: Yahoo Finance
